title: Glucocorticoid treatment of primary CNS lymphoma.
abstract: Glucocorticoid therapy may result in the rapid resolution of cerebral mass lesions in patients with primary CNS lymphoma. Since glucocorticoids will obscure the histological diagnosis of primary CNS lymphoma upon biopsy, steroids should be withheld if primary CNS lymphoma is a likely diagnosis by neuroradiological criteria. The lympholytic effect of glucocorticoids is mediated by cytoplasmic steroid receptors which are translocated to the nucleus and signal apoptosis. Glucocorticoid-induced apoptosis of lymphoid cells does not require wild-type p53 activity, seems not to depend on caspase activation, but is attenuated by the bcl-2 protooncogene product. Longterm glucocorticoid therapy of primary CNS lymphoma is not recommended because relapse is probably inevitable and because of the prominent side effects of long-term glucocorticoid treatment. Further, long-term glucocorticoid treatment is contraindicated in immunocompromised patients with primary CNS lymphoma.
authors.affiliation: Laboratory of Molecular Neuro-Oncology, Department of Neurology, University of Tübingen, Germany. michael.weller@uni-tuebingen.de
authors.forename: M
authors.initials: M
authors.lastname: Weller
mesh_terms: D016543:Central Nervous System Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D003937:Diagnosis, Differential; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D005938:Glucocorticoids